Results 31 to 40 of about 636,170 (221)

The potential of pirtobrutinib in multiple B-cell malignancies

Therapeutic Advances in Hematology, 2022
Bruton’s tyrosine kinase (BTK) is a critical downstream signaling element from the B-cell receptor (BCR) that has been effectively inhibited in B-cell cancers by irreversible, covalent inhibitors including ibrutinib and acalabrutinib.
Jeffrey L. Jensen, Anthony R. Mato, Camila Pena, Lindsey E. Roeker, Catherine C. Coombs   +4 more
doaj   +1 more source

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors. [PDF]

Blood Adv, 2023
Qi J, Endres S, Yosifov DY, Tausch E, Dheenadayalan RP, Gao X, Müller A, Schneider C, Mertens D, Gierschik P, Wist M, Jebaraj BMC, Stilgenbauer S.   +12 more
europepmc   +3 more sources

Btk inhibitors in atherosclerosis [PDF]

Blood, 2018
In this issue of Blood, Busygina et al provide provocative evidence that there is a potential role for Bruton tyrosine kinase (Btk) inhibitors in inhibiting platelet aggregation specifically at the site of unstable atherosclerotic plaques ...
openaire   +2 more sources

Btk/Itk Dual Inhibitors: Modulating Immunopathology And Lymphopenia For Covid-19 Therapy [PDF]

, 2021
Bruton\u27s tyrosine kinase (BTK) signaling is involved in innate immune responses and regulates the production of proinflammatory cytokines that can contribute to COVID-19 immunopathology.
McGee, M C, Huang, W S, August, A
core   +1 more source

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma

, 2023
Bruton’s tyrosine kinase (BTK) is a proven target in mantle cell lymphoma (MCL), an aggressive subtype of non-Hodgkin lymphoma. However, resistance to BTK inhibitors is a major clinical challenge. We here report that MALT1 is one of the top overexpressed
Vargas, Jovanny, McIntosh, Joseph, Wang, Wei, Bigcal, John Nelson, Liu, Yang, Li, Yijing, Yan, Fangfang, Badillo, Maria, Nie, Lei, Che, Yuxuan, Lee, Heng-Huan, Yao, Yixin, Chen, Zhihong, Wang, Michael, Flowers, Christopher R, Lin, Ruitao, Huang, Shengjian, Lian, Junwei, Jordan, Alexa, Cai, Qingsong, Flowers, Christopher R., Jiang, Vivian Changying   +21 more
core   +1 more source

Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials

Molecules, 2023
In the last few decades, there has been a growing interest in Bruton’s tyrosine kinase (BTK) and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) signaling pathway and affects B-cell proliferation and ...
Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, Anna Krupa, Dariusz Pawlak   +4 more
doaj   +1 more source

Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies

Frontiers in Oncology, 2020
The approval of BTK and PI3K inhibitors (ibrutinib, idelalisib) represents a revolution in the therapy of B cell malignancies such as chronic lymphocytic leukemia (CLL), mantle-cell lymphoma (MCL), diffuse large B cell lymphoma (DLBCL), follicular ...
Laura Ondrisova, Laura Ondrisova, Marek Mraz, Marek Mraz   +3 more
doaj   +1 more source

Discovery of Pteridine-7(8H)‑one Derivatives as Potent and Selective Inhibitors of Bruton’s Tyrosine Kinase (BTK)

, 2022
Bruton’s tyrosine kinase (BTK) is an attractive therapeutic target in the treatment of cancer, inflammation, and autoimmune diseases. Covalent and noncovalent BTK inhibitors have been developed, among which covalent BTK inhibitors have shown great ...
Honglin Li (19441), Limin Leng (6108116), Linjiang Tong (213513), Hua Xie (49932), Wenjie Sha (12025315), Dou Dou (12025312), Zhixiao Yu (12025321), Lili Zhu (219363), Yanyan Diao (1655920), Zihao Shen (11518000), Wenjie Li (6558), Zhenjiang Zhao (1655923), Yufang Xu (1655929), Zhuo Chen (135585), Rongrong Su (12025318), Haoming Song (848555), Lijuan Xie (1602031)   +16 more
core   +3 more sources

Observations on the use of Bruton’s tyrosine kinase inhibitors in SAR-CoV-2 and cancer

Journal of Hematology & Oncology, 2021
Bruton’s tyrosine kinase (BTK) inhibitors, drugs utilized in cancer, are being repurposed for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (COVID-19). Recently, BTK inhibitors acalabrutinib and ibrutinib have been found to protect against
Brooke Benner, William E. Carson
doaj   +1 more source

Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors

, 2021
Bruton tyrosine kinase (BTK) is linked to multiple signalling pathways that regulate cellular survival, activation, and proliferation. A covalent BTK inhibitor has shown favourable outcomes for treating B cell malignant leukaemia.
Min Li (12799), Er-Chieh Cho (6156662), Jui-Hua Hsieh (581219), Hsueh-Yun Lee (141907), Li-Chin Sung (3950120), Tony Eight Lin (5616098), Min-Wu Chao (137769), Jia-Huei Zheng (11825982), Tzu-Ying Sung (6039083), Chia-Ron Yang (313236), Kai-Cheng Hsu (177095)   +10 more
core   +1 more source